McGill Centre for Translational Research in Cancer (MCTRC)
Director: gerald [dot] batist [at] mcgill [dot] ca (Dr. Gerald Batist)
The great challenge faced by the oncology research community is in the translation of laboratory and clinical research data into clinical outcomes of benefit in the assessment, treatment and prevention of cancer. The McGill Centre for Translational Research in Cancer (MCTRC) was established in 1996, thanks to a generous endowment gift from the Goldfarb Family Foundation and the Alexander Family Foundation. Subsequent significant support included an endowment gift from the Montreal Breast Cancer Foundation. A 1997 article in the McGill Reporter outlines the origins of the McGill Centre for Translational Research in Cancer. (MCTRC McGill Reporter1997 [pdf])
Based at the Sir Mortimer B. Davis-Jewish General Hospital/Lady Davis Institute, the Centre provides the infrastructure to bring the investigators involved in "translational research" together to generate novel approaches to cancer treatment and adds a key element to the coordination of cancer researchers by providing a structured focus for these activities. At its inception, the Centre included members from the McGill Departments of Anatomy & Cell Biology, Biology, Medicine (Hematology and Experimental Medicine), Microbiology & Immunology, Oncology (Clinical Research, Basic Cancer Research, Pharmacokinetics), Pathology, Pediatrics and Pharmacology & Therapeutics. It has now become a multi-institutional organization that reaches throughout McGill and beyond, including basic and clinical researchers from 5 universities and 10 hospital-based or independent research institutes throughout Quebec. In 2000, it was repositioned as the Montreal Centre for Experimental Therapeutics in Cancer (MCETC) in the context of an application to the Canada Foundation for Innovation.
That same year, MCTRC/MCETC linked with the Centre de recherche clinique et evaluative en oncologie (CRCEO), based at the Centre de recherche of Hôtel Dieu du Quebec, to form the Axe Thérapeutique du Réseau de la Recherche sur le Cancer du FRSQ. Both partners have completed construction of their respective facilities. The Segal Cancer Centre opened in 2006, and integrates the laboratories and Clinical Research Unit of MCTRC/MCETC within a comprehensive cancer care centre.